Loading data for VYGR — first visit, this takes a few seconds.
Voyager Therapeutics, Inc.
3.48 +0.10 (2.96%)
3.50 -0.28%
- Market Cap
- $216.3M
- Volume
- 196K
- Dividend yield
- n/a
- Next earnings date
- Nov 9, 2026
Voyager Therapeutics, Inc. (VYGR) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $3.17M | n/a | -39.13% |
| EPS | -$0,40 | +$0,11 | +29.82% |
Metrics
- Bid
- 2.52
- Market Cap
- 216M
- Revenue (ttm)
- 34.5M
- Net Income (ttm)
- -108M
- 1.32
- -1.81
- n/a
- -2.74
- P/B (ttm)
- 1.22
- P/S (ttm)
- 6.28
- Earnings Date
- Nov 9, 2026
- Ask
- 4.31
- Volume
- 195,823
- Avg. Volume (20D)
- 593,731
- Open
- 3.34
- Previous Close
- 3.38
- Day's Range
- 3.33 - 3.50
- 52-Week Range
- 2.94 - 5.55
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Voyager Therapeutics, Inc.
View profile →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Industry Biotechnology
Sector Healthcare
IPO Date Nov 11, 2015
Employees 141
Stock Exchange NasdaqGS
Ticker Symbol VYGR